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Summary
Microtubules, composed of ab tubulin dimers, are dynamic
polymers of eukaryotic cells. They play important roles in various
cellular functions including mitosis. Microtubules exhibit differ-
ential dynamic behaviors during different phases of the cell cycle.
Inhibition of the microtubule assembly dynamics causes cell cycle
arrest leading to apoptosis; thus, qualifying them as important
drug targets for treating several diseases including cancer, neuro-
nal, fungal, and parasitic diseases. Although several microtubule-
targeted drugs are successfully being used in cancer chemother-
apy, the development of resistance against these drugs and their
inherent toxicities warrant the development of new agents with
improved efficacy. Several antimicrotubule agents are currently
being evaluated for their possible uses in cancer chemotherapy.
Benomyl, griseofulvin, and sulfonamides have been used as anti-
fungal and antibacterial drugs. Recent reports have shown that
these drugs have potent antitumor potential. These agents are
shown to inhibit proliferation of different types of tumor cells
and induce apoptosis by targeting microtubule assembly dynam-
ics. However, unlike vincas and taxanes, which inhibit cancer cell
proliferation in nanomolar concentration range, these agents act
in micromolar range and are considered to have limited toxic-
ities. Here, we suggest that these drugs may have a significant use
in cancer chemotherapy when used in combination with other
anticancer drugs.  2008 IUBMB
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MICROTUBULE DYNAMICS—DYNAMIC INSTABILITY
AND TREADMILLING
Microtubules play indispensable roles in cell division, cell
motility, cellular transport, maintaining cell polarity, and cell
signaling. Impairment in the functioning of microtubules leads
to an abnormal morphology of the cells and may even pose a
challenge to their survival leading to apoptosis. Microtubule po-
lymerization is a complex process involving a cooperative as-
sembly of ab tubulin heterodimers followed by GTP hydrolysis
(1). Each subunit of the tubulin heterodimer has one GTP mole-
cule bound to it. The a-subunit binds to GTP in an irreversible
manner while the GTP bound to b-tubulin is exchangeable (2)
and it hydrolyzes during polymerization.
Polymerization of microtubules occurs through two impor-
tant steps; nucleation and elongation. Initially, an oligomer con-
sisting of 6–12 ab tubulin dimers is formed in the nucleation
step. Further, GTP bound ab tubulin dimers add up to the nu-
cleus and lead to its elongation and formation of the protofila-
ment. After a rapid elongation phase, the assembly of microtu-
bules reaches the steady state, where the addition and the disso-
ciation of tubulin subunits at the ends of the microtubules are
balanced and there is no net increase in the polymer level. Hy-
drolysis of GTP introduces unusual equilibrium behaviors in
microtubules. Microtubules are labile polymers and they display
two types of dynamic behaviors, ‘‘treadmilling’’ and ‘‘dynamic
instability.’’ Treadmilling refers to a net addition of tubulin
dimers at the plus end coupled with a net dissociation at the
minus end producing a flow of subunits from one end of the
microtubule to the other without significantly changing the aver-
age length of microtubules (3, 4). Microtubule ends also alter-
nate between growing and shortening phases, which is called as
Dynamic instability (5). A transition from a growing phase to
a shortening phase is termed as a catastrophe while a transition
from a shortening phase to a growing phase is termed as a res-
cue (6). Using reconstituted microtubules, microtubule dynam-
ics have been investigated extensively in vitro by light micros-
copy. Microtubule dynamics in live cells are also studied by
time lapse video microscopy, either by labeling the individual
microtubules with fluorescent tubulin or by expressing GFP-
tubulin in the cells. Microtubule assembly and activity in the
cells is considered to be precisely regulated by several proteins,
called as microtubule associated proteins.
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Microtubule dynamics play an essential role in the proper
orientation and segregation of chromosomes during mitosis (7,
8). The plus ends of the microtubules undergo a series of ran-
dom elongations and shortenings in the cytoplasm to search
and bind the kinetochores of the chromosomes (9). Once the
plus ends attach to the kinetochores, the chromosomes are
translocated to the equatorial plane. Metaphase microtubules
are highly dynamic; however, at the onset of anaphase, micro-
tubule dynamics are stabilized to ensure the successful chromo-
somal segregation (10). Owing to the shortening of the micro-
tubules and due to the action of motor proteins, a tension is
generated in the microtubules, which leads to the poleward
movement of the chromosomes (11). A defect in this process
blocks the cells at mitosis by activating the spindle checkpoint.
The major proteins involved in the spindle checkpoint are
Mad1, Mad2, Mad3, Bub1, and Bub3 (12). Since microtubule
dynamics play important roles in various cellular functions
including mitosis, it is a potential drug target for several dis-
eases including cancer, neuronal diseases, fungal, and parasitic
diseases. Several antimicrotubule agents are now used as anti-
cancer drugs (13). In addition, some of the antimicrotubule
agents are also under clinical trials. On the basis of their
effects on microtubule assembly, microtubule-targeted drugs
are generally classified as either a depolymerizing agent or a
polymerizing agent.
Depolymerizing Agents
This class of agents inhibits microtubule assembly and
depolymerizes microtubules both in vitro and in vivo (Fig. 1).
Most of these agents either bind to the well characterized col-
chicine or vinblastine site on tubulin. While vinblastine binds
close to the exchangeable GTP site on the b-tubulin (14), col-
chicine site is located at the interface between a and b subunits
of the tubulin dimer (Fig. 2) (16). However, several of the
depolymerizing agents such as benomyl, estramustine, and
LY290181 have been shown not to compete with vinblastine
and colchicine for tubulin binding suggesting that these agents
bind to tubulin at sites distinct from the colchicine and vinblas-
tine binding sites (18–20). Vinblastine and colchicine inhibit
microtubule assembly in low substoichiometric concentrations
indicating that these agents inhibit microtubule assembly by
end poisoning (13, 21). Vinblastine or tubulin-colchicine com-
plex binds at the ends of microtubules and deter the addition of
new subunits. Further, these agents have also been shown to
kinetically stabilize the plus ends of microtubules. Present evi-
dence suggests that most of the antimitotic antitubulin agents
inhibit cell proliferation by perturbing microtubule dynamics
(13, 21).
POLYMERIZING AGENTS
This class of drugs promotes microtubule assembly and sta-
bilizes microtubules. Microtubule polymerizing agents include
paclitaxel (Fig. 1), docetaxel, and polyisoprenyl benzophenones.
Paclitaxel is a plant product from Taxus brevifolia. It is widely
used in the treatment of breast cancer, ovarian cancer, lung can-
cer, and several sarcomas. Paclitaxel binding site on tubulin is
well characterized. It binds on the inner surface of the microtu-
bules in a deep hydrophobic pocket on the b-tubulin (Fig. 2)
(15). Paclitaxel binding induces conformational changes in
tubulin structure, which stabilizes microtubules by increasing
the interaction between the tubulin subunits. Paclitaxel promotes
microtubule assembly and suppresses the growing and shorten-
ing dynamics of individual microtubules of tumor cells in cul-
ture (13).
In this review, we will be mainly focusing on three antimi-
crotubule agents namely benomyl, griseofulvin, and sulfona-
mides, which are currently attracting a lot of interest as poten-
tial anticancer agents. Benomyl and griseofulvin have been used
as antifungal compounds for a long time. However, these agents
are also shown to potently inhibit proliferation of various types
of cancer cells in culture. An active metabolite of benomyl, car-
bendazim, is presently undergoing clinical trials for the treat-
ment of advanced solid tumors (clinicaltrials.gov Identifier:
NCT00003709, CDR0000066817). Recent reports have shown
that griseofulvin specifically targets cells expressing tumor phe-
notype (22). Several anticancer drugs show high toxicities at
their therapeutic doses. These drugs other than inhibiting the
cancer cell proliferation also affect the healthy tissues of the
body. Many drugs including cisplatin, zoledronate, and mitomy-
cins exhibit significant level of nephrotoxicity (23, 24). Griseo-
fulvin at a concentration where it causes metaphase arrest
exhibits less toxicity (25). The use of the combination of griseo-
fulvin and nocodazole in nude mice bearing a colon adenocarci-
noma xenograft showed a significant reduction in the tumor size
as compared with the treatment with griseofulvin and nocoda-
zole alone (26). Use of low concentrations of nocodazole with
griseofulvin may reduce the toxicity of individual agents while
synergizing the anticancer effects of both the agents. Consider-
ing the fact that griseofulvin has the property of getting accu-
mulated in the keratin layers of the epidermis (27), it could
serve as a potential candidate for the treatment of skin cancers
either alone or in combination with other drugs. Similar obser-
vations have also been reported in case of ketoconazole and
nocodazole. Ketoconazole, an antifungal compound, when used
in combination with nocodazole reduced the minimum concen-
tration of nocodazole required to cause cell death (28). Further,
estramustine in combination with paclitaxel, docetaxel, and car-
boplatin has been shown to have positive results against hor-
mone refractory prostate cancer, with moderate and reversible
toxicities (29–31). Estramustine in combination with epirubucin
is presently under phase II clinical trial for the treatment of
prostate cancer (clinicaltrials.gov Identifier: NCT00218205).
Several sulfonamides such as E7010, E7070 have shown antitu-
mor activity in animal models (32). Further, E7010 and E7070
are currently undergoing clinical trials as anticancer agents
against various types of tumors and have shown tolerable toxic-
ity profiles and significant antitumor activity (33, 34).
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Benomyl
Benomyl belongs to the benzimidazole group of compounds
that are widely used as antifungal agents. Benomyl is selec-
tively toxic to microorganisms and is extensively used in agri-
culture against a range of fungal diseases of field crops and fruit
trees (WHO, report 1993 Environmental Health Criteria number
148: Benomyl). Benomyl is shown to exhibit differential sensi-
tivity against fungal and mammalian tubulin (35, 36). The
increased toxicity of benomyl to fungi is thought to be due to
its higher affinity for fungal tubulin than for mammalian tubulin
(36). Benomyl binds to mammalian tubulin with a Kd of  12
6 1.2 lM (18) indicating that it binds to mammalian tubulin
Figure 1. Structures of tubulin-targeted agents.
370 SINGH ET AL.
with a modest affinity rather than a weak affinity as was
believed earlier. Mutations in the b-tubulin gene, which either
increased the resistance or increased the sensitivity of yeast
cells to benomyl, suggested that benomyl targets tubulin in fun-
gal cells (37, 38). The exact binding site of benomyl on tubulin
is not yet known; however, several members of the benzimida-
zole group of compounds are shown to inhibit the binding of
colchicine both competitively and noncompetitively (35, 39).
On the basis of the structural similarities of benomyl and other
benimidazole analogues, benomyl was thought to bind near or
at the colchicine binding site. A study using site-directed muta-
genesis of b-tubulin gene in S. cerevisiae has indicated that the
benomyl binding site is located in the core of b-tubulin at a site
distinct from the colchicine site (40). Using colchicine fluores-
cence, Gupta et al. (2004) have found that the preincubation of
tubulin with benomyl neither had an affect on the binding of
colchicine to tubulin nor did it affect the kinetics of colchicine
binding to tubulin. In addition, benomyl was shown to bind to
the tubulin-colchicine complex (18). These observations lead to
the idea that benomyl and colchicine have different binding
sites on tubulin. Benomyl also does not bind to the vinblastine
site on tubulin (18). Further, it alters the far-UV CD spectra of
tubulin and also reduces the number of accessible cysteine resi-
dues in tubulin, indicating that it induces conformational
changes in tubulin (18).
Benomyl weakly inhibits the assembly of tubulin subunits
into microtubules in vitro (18). For example, half-maximal inhi-
bition of polymerization occurred in the presence of 70 lM
benomyl. At this concentration nearly 85% of the soluble tubu-
lin is calculated to be bound to benomyl. Thus, in contrast to
colchicine and vinblastine benomyl does not inhibit microtubule
polymerization by end-poisoning mechanism; rather, benomyl-
tubulin complex copolymerizes along with free tubulin into
microtubules. Though benomyl weakly inhibits microtubule
assembly, it significantly perturbs the dynamic instability of
microtubules in vitro. Benomyl reduces the growing and short-
ening rates at the plus ends of bovine brain microtubules
in vitro. Additionally, it increases the time spent by each micro-
tubule in the attenuated state and significantly reduces the
dynamicity of microtubules. Benomyl-induced conformational
changes may reduce the rate of tubulin addition at the plus ends
while the copolymerization of benomyl with tubulin into the
microtubule lattice may reduce the shortening rate by increasing
the stability of the polymer (18).
Benomyl inhibits cell-cycle progression at mitosis and also
induces apoptotic cell death (a putative mechanism of action of
benomyl has been depicted in Fig. 3) (18, 41). In the lower in-
hibitory concentration range of benomyl (at or near half maxi-
mal inhibitory concentration range); though the cells form nor-
mal spindles, they do not exhibit proper chromosomal segrega-
tion. Benomyl suppresses the assembly of microtubule in HeLa
cells. Benomyl treated cells also show a decrease in the spindle
length and the interpolar distance. Benomyl is shown to perturb
the microtubule-kinetochore interactions and reduce the distance
between the sister kinetochore pairs indicating that it reduces
the tension across the kinetochores. The loss of tension at the
kinetochores activates the spindle checkpoint proteins, thereby
inducing a mitotic block. Benomyl-induced mitotic arrest in
HeLa cells is accompanied by hyper phosphorylation of Bcl-2
and the release of Bax from the Bcl-2-Bax complex indicating
Figure 2. Crystal structure of ab-tubulin heterodimers (2) showing binding sites of different anticancer agents. The binding sites of
vinblastine (14), paclitaxel (15), and colchicine (16) are shown. Sulfonamides are thought to bind to the colchicine binding site (17).
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that benomyl significantly increased the ratio of free Bax (41).
The increase in the ratio of free Bax causes the formation of
Bax–Bax homodimer, facilitating apoptosis.
Griseofulvin
Griseofulvin is an antifungal antibiotic produced by various
species of Penicillium (27). Griseofulvin has been extensively
used for the treatment of ring worm (Tinea capitis) and other
dermatophyte infections and is considered to be relatively of
low toxicity to human beings (42). Griseofulvin accumulates in
the keratin layers of the epidermis and inhibits the fungal
growth (27). Although its mechanism of action is not clearly
understood it was thought to inhibit mitosis in sensitive fungi
by disrupting microtubules (43). Griseofulvin, similarly inhibits
the proliferation of mammalian cells by targeting microtubules
(44, 45). Griseofulvin inhibits microtubule assembly concurrent
with inhibition of mitosis in echinoderm eggs (46) and it inhib-
its mitosis in 3T3 cells in association with depolymerization of
the spindle microtubules (44). At lower concentrations, it inhib-
its mitosis at the metaphase anaphase transition in HeLa cells in
the absence of significant depolymerization of spindle microtu-
bules (47, 48). Griseofulvin induces cell cycle arrest at G2/M
transition; this is characterized by an abnormal spindle forma-
tion, increase in the cyclin B1/cdc2 kinase activity and down
regulation of myt-1 protein expression (26). Additionally, grise-
ofulvin induces apoptosis in cells which is preceded by caspase
3 activation, Bcl-2 hyperphosphorylation and activation of NF-
jB pathway (26, 49). Cells treated with half maximal inhibitory
concentration of griseofulvin have normal bipolar spindles; but
they show defects in chromosomal segregation (48). Several of
the chromosomes in the treated cells fail to align at the equato-
rial plane during metaphase (48). At twice the half maximal in-
hibitory concentration (2 3 IC50), griseofulvin disrupts spindle
microtubules and depletes most of the mitotic microtubules at
relatively high concentrations. Griseofulvin does not have a dis-
tinct effect on the interphase microtubules. Even at twice IC50
concentrations of griseofulvin, no detectable change in the inter-
phase microtubules has been observed. However, at higher con-
centrations (6 3 IC50), griseofulvin significantly depolymerizes
interphase microtubules of HeLa cells. Griseofulvin has been
shown to inhibit the aggregation of multiple centrioles in
SCC114 and N115 mouse neuroblastoma cell lines (22). These
cell lines show an increase in the formation of multipolar spin-
dles in the presence of increasing concentration of griseofulvin
(22). The cells with bipolar spindles survive in the presence of
griseofulvin while the cells with multipolar spindle end up in
apoptosis (22).
Griseofulvin binds to tubulin in vitro with a weak affinity
(Kd, 300 lM) (48). Griseofulvin does not significantly reduce
the polymer mass of tubulin in vitro; the inhibition of brain
tubulin polymerization requires very high concentrations of gris-
eofulvin (44, 45, 48). Griseofulvin does not alter the sediment-
able polymer mass of reconstituted microtubules suggesting that
Figure 3. A schematic representation depicting the mechanism of inhibition of cell proliferation by Benomyl. Benomyl suppresses
microtubule dynamics causing improper chromosomal segregation and mitotic arrest of cells. Benomyl induces hyperphosphoryla-
tion of Bcl-2 and dissociation of Bcl2-Bax complex promoting Bax–Bax homodimerization. An increase in the ratio of Bax–Bax
homodimers leads to the execution of apoptotic events like cleavage of PARP and fragmentation of DNA.
372 SINGH ET AL.
it does not sequester tubulin. In contrast to its weak effect on
polymer mass, griseofulvin strongly suppresses the dynamics of
reconstituted microtubules in vitro (48). Griseofulvin (5 lM)
reduces the rates of growing and shortening by 50 and 70%,
respectively. Further, it strongly reduces the catastrophe fre-
quency and increases the percent of time spent by microtubule
in the attenuated state. Griseofulvin even at low concentrations
exerts a strong suppressive effect on the dynamics of the indi-
vidual microtubules; it has no significant effect on the extent of
net microtubule assembly indicating that griseofulvin may be
exerting its inhibitory effect on cell proliferation by suppressing
the dynamic behavior of microtubules (48). Griseofulvin in
combination with nocodazole enhances the effect of nocodazole
against the colon cancer cells in vivo (26). Since griseofulvin is
known to have less toxicity in human, it can be used in combi-
nation with other anticancer drugs in adjuvant therapy.
Sulfonamides
Sulfonamides are known to interact with different cellular tar-
gets and produce diverse pharmacological effects. In addition to
their antibacterial, antiviral, antidiabetic, and antithyroid activ-
ities, several sulfonamides are currently undergoing clinical trials
as anticancer agents (clinicaltrials.gov Identifier: NCT00297089).
Antitumor sulfonamides have been mainly divided into two
groups based on their structure-activity relationship. One group is
represented by N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide
(E7070) and its analogues and the other group by N-[2-[(4-
hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzene sulfona-
mide (E7010) (Fig. 1). Indole sulfonamides inhibit the binding of
colchicine to tubulin; however, unlike colchicine, sulfonamides
do not increase the GTPase activity of tubulin indicating that
these agents bind to tubulin by different mechanisms (50). Dock-
ing studies also indicated that E7010 and the indole sulfonamides
derived from E7010, may have distinct binding modes at the col-
chicine site on tubulin (51). The indole sulfonamides like E-
68384 and E-68378 (Fig. 1) are shown to inhibit microtubule po-
lymerization in vitro (17). Further, some of the indole sulfona-
mides are found to suppress the dynamicity of individual microtu-
bules by reducing the growing and shortening rates and by inhibi-
ting the catastrophe and rescue frequencies, while increasing the
pause state (17). The binding of free sulfonamide molecules or
sulfonamide-tubulin complexes either at the microtubule ends or
their incorporation into the microtubule lattice may stabilize
microtubule lattice and prevent further addition of tubulin dimers
at the ends. The indole sulfonamides inhibit the proliferation of
HeLa cells by blocking the cells at mitosis. At half maximal in-
hibitory concentration for cell proliferation (IC50), the indole
sulfonamides depolymerize spindle microtubules and perturb the
chromosome organization without significantly affecting the
interphase microtubules. The spindle microtubules are highly
dynamic and more labile than the interphase microtubules and
this may be the basis of the differential effects of indole sulfona-
mides on the microtubules of mitotic and interphase cells. How-
ever, high concentrations (3 3 IC50) of these agents are found to
depolymerize microtubules of both interphase and mitotic cells.
Abnormal spindle organization, with condensed ball shaped chro-
mosomes is induced by these drugs, which prevents the mitotic
progression of these cells. Sulfonamides induce the formation of
multinucleated polyploid cells, which may be due to the occur-
rence of nuclear division without being followed by cytokinesis
(52). The basis of the antimitotic activity of sulfonamides is
somewhat similar to that of known antimicrotubule agents; it
involves suppression of microtubule dynamics (17).
CONCLUSION
In spite of their potent anticancer action, many of the antimi-
crotubule drugs have limited clinical use because of their strong
toxic effects. Another limiting factor lies in the inherent or
acquired resistance of the tumors towards these drugs. Tumors
may develop resistance against a particular drug due to the
overexpression of drug efflux pumps, mainly P-glycoprotein and
multidrug resistance associated protein 1, which pump out the
drug from the cells and reduce the intracellular concentration of
the drug (53). Another modus operandi adopted by oncogenic
cells involves mutations in the genes encoding a and b subunits
of tubulin, which reduce the binding of a drug to tubulin (54).
In addition, differential expression of tubulin isotypes may also
contribute to the development of drug resistance. Discovery of
new antimicrotubule drugs with novel mechanism of action may
be helpful to overcome these problems. Another way to over-
come these shortcomings might lie in the combination therapy,
which reduces the doses of individual drugs, thereby lessening
their toxicities (13, 20, 28–31). Griseofulvin, benomyl, and sul-
fonamides are weak antimicrotubule agents and these agents are
considered to have less harmful side effects compared with the
highly potent antimicrotubule agents such as vincas and taxanes.
Therefore, these agents can be used in combination with low
doses of other microtubule targeted drugs to have a synergistic
inhibitory effect on the proliferation of cancer cells in the
absence of significant toxicity.
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